New hope for tough lung cancer: early trial launches in china
NCT ID NCT06799286
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug combination (BMS-986489) in about 10 Chinese patients whose small cell lung cancer has returned or stopped responding to treatment. The main goals are to check safety and how the drug moves through the body, while also looking for signs that it might shrink tumors. This is not a cure, but aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Linyi, Shandong, 276001, China
-
Local Institution - 0002
Shanghai, 200120, China
-
Local Institution - 0003
Jinan, Shandong, 250117, China
-
Local Institution - 0004
Beijing, Beijing Municipality, 100142, China
-
Local Institution - 0005
Hangzhou, Zhejiang, 310016, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can head radiation stop lung cancer from spreading to the brain?
- New hope for tough lung cancer: drug plus radiation combo shows promise in early trial
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- Laser and Light-Sensitive drug shrink lung tumors in early trial
- New drug candidate CBX-12 tested in patients with Hard-to-Treat cancers
- New hope for frail lung cancer patients: immune drug may delay tumor growth